1.0	Saturday	have	issue	O	DATE
1.0	this	have pitch	activist	0	0
1.0	herceptin	have receive	approval in market	0	0
1.0	breast cancer	have	curse	O	O
1.0	breast cancer	have	cases	O	O
1.0	health fund	buy	drug	0	0
1.0	Lancet	have	issue	O	ORGANIZATION
1.0	Herceptin	be	be test on patient	MISC	0
1.0	The breast-cancer drug Herceptin	be engineered antibody	that adhere to so-called her-2 protein on tumour cell 's surface	0	0
1.0	herceptin	have receive	approval in key market	0	0
1.0	The breast-cancer drug Herceptin	reduce risk by	52 percent at two-year mark	0	PERCENT
1.0	Herceptin	be	be test on patient with disease in its stage	MISC	0
1.0	wonder drug	be	find	0	0
1.0	herceptin	have already receive	approval in market	0	0
1.0	Herceptin	have	apparent benefit	0	0
1.0	it	block	instruction for cell	0	0
1.0	breast cancer	have	form	O	O
1.0	The breast-cancer drug Herceptin	be antibody	that adhere	0	0
1.0	The breast-cancer drug Herceptin	be engineered antibody	that adhere to her-2 protein on tumour cell 's surface	0	0
1.0	The breast-cancer drug Herceptin	reduce	risk of cancer	0	0
1.0	fifty-nine woman	be in	Herceptin group	0	MISC
1.0	woman	be with	early-stage breast cancer	0	0
1.0	trial	be good news for	woman with her-2 early breast cancer	0	0
1.0	patient	be with	disease in its early stage	0	0
1.0	Herceptin	be	be now test on patient with disease	MISC	DATE
0.9289387536545167	The breast-cancer drug Herceptin	risk of	cancer	0	0
1.0	catastrophic side-effect	emerge for	trastuzumab	0	0
1.0	action	be	vital	0	0
1.0	The breast-cancer drug Herceptin	be engineered antibody	that adhere	0	0
1.0	study	appear in	Saturday 's issue	0	DATE
1.0	trial	be news for	woman with her-2 early breast cancer	0	0
1.0	Royal Marsden Hospital	have	Ian Smith	PERSON	ORGANIZATION
1.0	The breast-cancer drug Herceptin	reduce	risk of premature death of cancer	0	0
1.0	Saturday	in	issue of Lancet alongside commentary	DATE	ORGANIZATION
1.0	two US trial	find in	2005	LOCATION	DATE
1.0	The breast-cancer drug Herceptin	reduce	risk of death of cancer	0	0
1.0	Herceptin	be	why be now test on patient with disease in its early stage	MISC	DATE
1.0	this	have pitch activist against	group	0	0
1.0	trial	be news for	woman with her-2 positive early breast cancer	0	0
1.0	Herceptin	be	why be now test on patient with disease	MISC	DATE
1.0	US trial	find in	2005	LOCATION	DATE
1.0	herceptin	have already receive	approval	0	0
1.0	tumour cell	have	surface	O	O
1.0	question	remain	unresolved	0	0
1.0	The breast-cancer drug Herceptin	use with	chemotherapy	0	0
1.0	approval	be in	key market	0	0
1.0	death	have	risk	O	O
0.9066283379515536	Herceptin 's apparent benefit	risk of	damage	0	0
1.0	Herceptin	be	why be test	MISC	0
1.0	Herceptin	be	why be test on patient with disease in its early stage	MISC	0
1.0	Herceptin	be	be now test	MISC	DATE
1.0	herceptin	treat	her-2 cancer	0	0
1.0	The breast-cancer drug Herceptin	be	engineered	0	0
0.9289387536545167	The breast-cancer drug Herceptin	risk of	premature death	0	0
1.0	herceptin	treat her-2 cancer in	its stage	0	0
1.0	health fund	devote to	problem	0	0
1.0	new study	appear in	Saturday 's issue	0	DATE
1.0	herceptin	have already receive	approval in key market	0	0
1.0	Herceptin	be	be now test on patient with disease in its early stage	MISC	DATE
1.0	women	have	percent	PERCENT	O
1.0	women	have	fifth	ORDINAL	O
1.0	The breast-cancer drug Herceptin	reduce	risk of premature death of early-stage cancer	0	0
1.0	long	remain	unclear	0	0
1.0	cancer	have	risk	O	O
1.0	trial	be	news	0	0
0.9066283379515536	Herceptin 's apparent benefit	risk of	cardiac damage	0	0
1.0	trial	be good news for	woman with her-2 breast cancer	0	0
1.0	long-term side-effect	emerge for	trastuzumab	0	0
1.0	side-effect	emerge for	trastuzumab	0	0
1.0	The breast-cancer drug Herceptin	reduce risk by	52 percent at mark	0	PERCENT
1.0	signal	destroy	tumour cell	0	0
1.0	trial	be	good news	0	0
1.0	trial	be news for	woman with her-2 positive breast cancer	0	0
1.0	it	block	instruction	0	0
1.0	Herceptin	be	why be test on patient with disease in its stage	MISC	0
0.9134300175268706	The breast-cancer drug Herceptin	market by	US genentech	0	LOCATION
1.0	90	die in	control group	NUMBER	0
1.0	woman	be with	her-2 positive early breast cancer	0	0
1.0	Herceptin	be	be now test on patient with disease in its stage	MISC	DATE
1.0	study	appear in	Saturday 's issue of Lancet	0	DATE
1.0	wonder drug	be find for	curse of breast cancer	0	0
1.0	Herceptin	be	why be test on patient with disease	MISC	0
1.0	The breast-cancer drug Herceptin	be engineered antibody	that adhere to so-called her-2 protein	0	0
1.0	health fund	buy	costly drug	0	0
1.0	trial	be good news for	woman with her-2 positive breast cancer	0	0
1.0	disease	be in	its early stage	0	0
0.01311160545069101	The breast-cancer drug Herceptin	reduce by	52 percent at two-year mark	0	PERCENT
1.0	The breast-cancer drug Herceptin	reduce	risk of death	0	0
1.0	Herceptin	be	why be now test	MISC	DATE
1.0	scarce health fund	buy	drug	0	0
0.9289387536545167	The breast-cancer drug Herceptin	risk of	early-stage cancer	0	0
1.0	heart failure	have	cases	O	O
1.0	trial	be good news for	woman	0	0
1.0	trial	be good news for	woman with her-2 positive early breast cancer	0	0
1.0	Ian Smith	be of	Royal Marsden Hospital	PERSON	ORGANIZATION
1.0	this	have pitch activist against	other group	0	0
0.9289387536545167	The breast-cancer drug Herceptin	risk of	death	0	0
1.0	herceptin	have receive	approval	0	0
1.0	The breast-cancer drug Herceptin	be engineered antibody	that adhere to her-2 protein	0	0
1.0	Herceptin	be	be test	MISC	0
1.0	The breast-cancer drug Herceptin	reduce	risk of premature death	0	0
1.0	trial	be news for	woman with her-2 breast cancer	0	0
1.0	The breast-cancer drug Herceptin	reduce risk by	52 percent	0	PERCENT
1.0	Herceptin	be	why be now test on patient with disease in its stage	MISC	DATE
1.0	Switzerland	have	Roche	PERSON	LOCATION
1.0	scarce health fund	devote to	other problem	0	0
1.0	The breast-cancer drug Herceptin	reduce	risk of death of early-stage cancer	0	0
1.0	this	have pitch	breast-cancer activist	0	0
1.0	an adjuvant -- a follow-up drug -- among women with early-stage HER-2 positive cancer	have	stages	O	O
1.0	survival	have	hope	O	O
1.0	Roche	have	website	O	ORGANIZATION
1.0	health fund	devote to	other problem	0	0
1.0	trial	be news for	woman	0	0
1.0	scarce health fund	devote to	problem	0	0
0.9134300175268706	The breast-cancer drug Herceptin	market by	US biotech genentech	0	LOCATION
1.0	herceptin	treat her-2 cancer in	its advanced stage	0	0
1.0	Herceptin	be	why be now test on patient	MISC	DATE
1.0	doctor	lead by	Ian Smith	0	PERSON
1.0	Herceptin	be	be now test on patient	MISC	DATE
1.0	The breast-cancer drug Herceptin	be antibody	that adhere to her-2 protein	0	0
1.0	its	have	stages	O	O
1.0	Herceptin	be	why be test on patient	MISC	0
1.0	genentech	be by	US	0	LOCATION
1.0	The breast-cancer drug Herceptin	reduce	risk of early-stage cancer	0	0
1.0	woman	be with	her-2	0	0
0.9134300175268706	The breast-cancer drug Herceptin	market by	US biotech giant genentech	0	LOCATION
1.0	The breast-cancer drug Herceptin	be antibody	that adhere to so-called her-2 protein on tumour cell 's surface	0	0
1.0	The breast-cancer drug Herceptin	reduce	risk	0	0
1.0	new study	appear in	Saturday 's issue of Lancet	0	DATE
1.0	tumour cell	on	surface	0	0
1.0	The breast-cancer drug Herceptin	be antibody	that adhere to so-called her-2 protein	0	0
1.0	early action	be	vital	0	0
1.0	recurrence	have	risk	O	O
1.0	catastrophic long-term side-effect	emerge for	trastuzumab	0	0
1.0	Herceptin	have	benefits	O	O
0.9134300175268706	The breast-cancer drug Herceptin	market by	US giant genentech	0	LOCATION
1.0	Herceptin costs	have	course	O	O
0.01311160545069101	The breast-cancer drug Herceptin	reduce by	52 percent	0	PERCENT
1.0	it	block	instruction for cell divide	0	0
1.0	doctor	lead by	Ian Smith of Royal Marsden Hospital	0	ORGANIZATION
1.0	Herceptin	be	be test on patient with disease in its early stage	MISC	0
1.0	wonder drug	be find for	curse	0	0
1.0	The breast-cancer drug Herceptin	be antibody	that adhere to her-2 protein on tumour cell 's surface	0	0
0.01311160545069101	The breast-cancer drug Herceptin	reduce by	52 percent at mark	0	PERCENT
1.0	scarce health fund	buy	costly drug	0	0
1.0	doctor	lead in	London	0	LOCATION
1.0	their	have	lifetime	O	O
1.0	Herceptin	be	be test on patient with disease	MISC	0
1.0	damage	have	risks	O	O
1.0	people	have	death rate	O	O
1.0	Roche	accord to	website	ORGANIZATION	0
